Recruiting

JAK Inhibitors for Alopecia Areata

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Alopecia+3

+ Alopecia Areata

+ Hair Diseases

From 2 to 80 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: July 2024
See protocol details

Summary

Principal SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Study ContactRu Dai, MDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 29, 2024

Actual date on which the first participant was enrolled.

The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disease characteristics and patients profiles that are considered good candidates for JAKi in the daily practice. Furthermore, we intended to investigate the efficacy and safety of JAK Inhibitors in patients With AA, as well as to provide clinical evidence for the clinicians and patients when they formulate individualized treatment plans.

Official TitleEfficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
NCT06573593
Principal SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Study ContactRu Dai, MDMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

150 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 2 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

AlopeciaAlopecia AreataHair DiseasesHypotrichosisSkin DiseasesSkin and Connective Tissue Diseases

Criteria

3 inclusion criteria required to participate
Patients with alopecia areata between 2 to 18 years old
Patients diagnosed with alopecia areata according to AA guideline
AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
5 exclusion criteria prevent from participating
Patients had previously received hair implants
Other alopecia
Other diseases may induce alopecia including psoriasis, lichen planus, et al.
Unable to estimate SALT score at baseline or at follow-up
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Second Affiliated Hospital, School of Medicine, Zhejiang University, China

Hangzhou, ChinaOpen Second Affiliated Hospital, School of Medicine, Zhejiang University, China in Google Maps
Recruiting
One Study Center
JAK Inhibitors for Alopecia Areata | PatLynk